

Mini Review

Brain-derived Neurotrophic Factor

DEVIN K. BINDER^{a,*} and HELEN E. SCHARFMAN^b

^aDepartment of Neurological Surgery, M779 Moffitt Hospital, Box 0112, University of California, San Francisco, CA 94143-0112, USA; ^bCenter for Neural Recovery and Rehabilitation Research, Helen Hayes Hospital, West Haverstraw, NY and Departments of Pharmacology and Neurology, Columbia University, New York, NY, USA

(Received 22 March 2004; Revised 10 May 2004)

HISTORY

Nerve growth factor (NGF) was discovered in the early 1950s due to its trophic (survival- and growth-promoting) effects on sensory and sympathetic neurons (Levi-Montalcini and Hamburger, 1951). In 1982, brain-derived neurotrophic factor (BDNF), the second member of the “neurotrophin” family of neurotrophic factors, was shown to promote survival of a subpopulation of dorsal root ganglion neurons, and subsequently purified from pig brain (Barde *et al.*, 1982). Since then, other members of the neurotrophin family such as neurotrophin-3 (NT-3) (Maisonpierre *et al.*, 1990) and neurotrophin-4/5 (NT-4/5) (Hallbook *et al.*, 1991; Ip *et al.*, 1992) have been described, each with a distinct profile of trophic effects on subpopulations of neurons in the peripheral and central nervous systems.

GENE AND PROTEIN STRUCTURE

The BDNF gene (in humans mapped to chromosome 11p) has four 5' exons (exons I–IV) that are associated with distinct promoters, and one 3' exon (exon V) that encodes the mature BDNF protein (Metsis *et al.*, 1993; Timmusk *et al.*, 1993). Eight distinct mRNAs are transcribed, with transcripts containing exons I–III expressed predominantly in brain and exon IV found in lung and heart (Timmusk *et al.*, 1993).

BDNF shares about 50% amino acid identity with NGF, NT-3 and NT-4/5. Each neurotrophin consists of a noncovalently-linked homodimer and contains (1) a signal peptide following the initiation codon; and (2) a pro-region containing an N-linked glycosylation site. Initially produced as proneurotrophins, prohormone convertases

such as furin cleave the proneurotrophins (M.W. ~30 kDa) to the mature neurotrophin (M.W. ~14 kDa) (Chao and Bothwell, 2002). Proneurotrophins have altered binding characteristics and distinct biologic activity in comparison with mature neurotrophins (Lee *et al.*, 2001a,b). Neurotrophins also share a distinctive three-dimensional structure containing two pairs of antiparallel β -strands and cysteine residues in a cystine knot motif.

BDNF SIGNAL TRANSDUCTION

Each neurotrophin binds one or more of the tropomyosin-related kinase (trk) receptors, members of the family of receptor tyrosine kinases (Patapoutian and Reichardt, 2001). Ligand-induced receptor dimerization results in kinase activation; subsequent receptor autophosphorylation on multiple tyrosine residues creates specific binding sites for intracellular target proteins, which bind to the activated receptor via SH2 domains (Barbacid, 1994; Patapoutian and Reichardt, 2001). These include PLC γ 1 (phospholipase C), p85 (the noncatalytic subunit of PI-3 kinase) and Shc (SH2-containing sequence); activation of these target proteins can then lead to a variety of intracellular signalling cascades such as the Ras-MAP (mitogen-activated protein) kinase cascade and phosphorylation of cyclic AMP-response element binding protein (CREB) (Patapoutian and Reichardt, 2001; Segal, 2003).

TrkA binds NGF (with low-affinity binding by NT-3 in some systems); trkB binds BDNF and NT-4/5 with lower-affinity binding by NT-3; and trkC binds NT-3 (Barbacid, 1994). Trk receptors exist in both a full-length (trkB.FL) form as well as truncated (trkB.T1, trkB.T2) forms lacking the kinase domain (Eide *et al.*, 1996; Fryer *et al.*, 1997).

*Corresponding author. Tel.: +1-415-502-2965. Fax: +1-415-753-1772. E-mail: dbinder@itsa.ucsf.edu

Although most functions attributed to BDNF are associated with full-length trkB, several roles have been suggested for truncated receptors, including growth and development (Fryer *et al.*, 1997; Yacoubian and Lo, 2000; Luikart *et al.*, 2003) and negative modulation of trkB receptor expression and function (Eide *et al.*, 1996; Haapasalo *et al.*, 2001; Haapasalo *et al.*, 2002). Expression of truncated trk receptors on astrocytes is upregulated following injury (Frisen *et al.*, 1993) and may modulate neuronal vulnerability (Saarelainen *et al.*, 2000a,b) and sequestration of BDNF in astrocytes (Biffo *et al.*, 1995; Roback *et al.*, 1995; Alderson *et al.*, 2000). Recent studies have shown that BDNF activates glial calcium signalling by truncated trk receptors (Climent *et al.*, 2000; Rose *et al.*, 2003).

In addition, all of the neurotrophins bind to the p75 receptor, designated p75^{NTR}. p75^{NTR}, related to proteins of the tumor necrosis factor (TNFR) superfamily, has a glycosylated extracellular region involved in ligand binding, a transmembrane region, and a short cytoplasmic sequence lacking intrinsic catalytic activity (Chao and Hempstead, 1995; Dechant and Barde, 2002). Neurotrophin binding to p75^{NTR} is linked to several intracellular signal transduction pathways, including nuclear factor- κ B (NF- κ B), Jun kinase and sphingomyelin hydrolysis (Dechant and Barde, 2002). P75^{NTR} signalling mediates biologic actions distinct from those of the trk receptors, notably the initiation of programmed cell death (apoptosis) (Casaccia-Bonnel *et al.*, 1996; Frade *et al.*, 1996; Roux *et al.*, 1999; Dechant and Barde, 2002). It has also been suggested that p75 may serve to determine neurotrophin binding specificity (Esposito *et al.*, 2001; Lee *et al.*, 2001a,b; Zaccaro *et al.*, 2001).

BDNF GENE REGULATION

A multitude of stimuli have been described that alter BDNF gene expression in both physiologic and pathologic states (Lindholm *et al.*, 1994). For example, light stimulation increases BDNF mRNA in visual cortex (Castrén *et al.*, 1992), osmotic stimulation increases BDNF mRNA in the hypothalamus (Castrén *et al.*, 1995; Dias *et al.*, 2003), and whisker stimulation increases BDNF mRNA expression in somatosensory barrel cortex (Rocamora *et al.*, 1996). Electrical stimuli that induce long-term potentiation (LTP) in the hippocampus, a cellular model of learning and memory, increase BDNF and NGF expression (Patterson *et al.*, 1992; Castrén *et al.*, 1993; Bramham *et al.*, 1996). Even physical exercise has been shown to increase NGF and BDNF expression in hippocampus (Neeper *et al.*, 1995). Interestingly, BDNF levels vary across the estrous cycle, which correlate with its effects on neural excitability (Scharfman *et al.*, 2003).

Distinct BDNF 5' exons are differentially regulated by stimuli such as neural activity. For example, exons I–III, but not exon IV, increase after kainic acid-induced

seizures (Timmusk *et al.*, 1993) or other stimuli that increase activity (Lauterborn *et al.*, 1996; Tao *et al.*, 2002). Protein synthesis is required for the effects of activity on exons I and II, but not III and IV, raising the possibility that the latter act as immediate early genes (Lauterborn *et al.*, 1996; Castrén *et al.*, 1998). The transcription factor CaRF activates transcription of exon III under the control of a calcium response element, CaRE1 (Tao *et al.*, 2002). CREB, which can be stimulated by diverse stimuli ranging from activity to chronic antidepressant treatment (Nibuya *et al.*, 1995, 1996; Shieh *et al.*, 1998; Tao *et al.*, 1998; Shieh and Ghosh, 1999), also modulates exon III transcription. Recent evidence also indicates that neural activity triggers calcium-dependent phosphorylation and release of methyl-CpG binding protein 2 (MeCP2) from BDNF promoter III to derepress transcription (Chen *et al.*, 2003).

LOCALIZATION, TRANSPORT AND RELEASE

BDNF and trkB mRNA have a widespread distribution in the central nervous system (Merlio *et al.*, 1993; Conner *et al.*, 1997). BDNF and trkB protein immunoreactivity is also widespread (Conner *et al.*, 1997; Yan *et al.*, 1997a, b; Drake *et al.*, 1999). Like BDNF mRNA, constitutive BDNF protein expression is particularly high in the hippocampus, where the mossy fibre axons of dentate granule cells display BDNF immunoreactivity (Conner *et al.*, 1997).

Unlike the classical target-derived trophic factor model in which neurotrophins—such as NGF—are retrogradely transported, there is now abundant evidence that BDNF is also anterogradely transported in brain. First, BDNF protein is localized to nerve terminals (Conner *et al.*, 1997), and pathway transection or axonal transport inhibition abrogates this terminal expression (Altar *et al.*, 1997; Conner *et al.*, 1997; Altar and DiStefano, 1998). Second, higher-resolution studies have shown that BDNF is associated with dense-core vesicles (Fawcett *et al.*, 1997; Altar and DiStefano, 1998), which are the primary site for neuropeptide storage and release from nerve terminals. Third, further functional studies have supported the anterograde transport hypothesis (Fawcett *et al.*, 1998, 2000). Fourth, pro-BDNF is shuttled from the trans-Golgi network into secretory granules, where it is cleaved by prohormone convertase 1 (PC1) (Farhadi *et al.*, 2000).

In addition, emerging evidence suggests that both BDNF and trk receptors may undergo regulated intracellular transport. For example, seizures lead to redistribution of BDNF mRNA from hippocampal CA3 cell bodies to their apical dendrites (Bregola *et al.*, 2000; Simonato *et al.*, 2002). Trk signalling is now thought to include retrograde transport of intact neurotrophin–trk complexes to the neuronal cell body (Miller and Kaplan, 2001; Ginty and Segal, 2002).

Recent evidence indicates that neurotrophins are released acutely following neuronal depolarization




FIGURE 1 Multiple potential effects of local BDNF release at glutamatergic synapses. **LEFT:** Postsynaptic mechanisms. *Top:* BDNF released from dense core vesicles diffuses across the synaptic cleft to activate full-length trkB receptors (shown dimerized, trkB TK+) located at synapses on postsynaptic dendritic spines. *Bottom:* Postsynaptic signal transduction leads to protein phosphorylation, such as the NR2B subunit of the NMDA receptor, as well as other actions, leading to enhanced synaptic transmission. Note that the site of transcription could be the nucleus, as shown, or occur locally in the dendrite. **CENTER:** Presynaptic mechanisms. *Top:* BDNF activates, in an autocrine fashion, full-length trkB receptors on the plasma membrane of the axon terminal. *Bottom:* Presynaptic trkB activation leads to increased neurotransmitter release by several potential mechanisms. **RIGHT:** Synaptic modulation by glial cells. *Top:* When BDNF is released into the synaptic cleft, it may bind to receptors on juxtaposed glial cells, such as truncated trkB (trkB TK -), possibly full-length trkB (not shown) or p75 receptors. *Bottom:* Activation of truncated trkB has the potential to modulate glial Ca^{2+} signalling, and p75 activation can initiate other pathways; both could ultimately lead to changes in synaptic transmission.

(Griesbeck *et al.*, 1999; Mowla *et al.*, 1999; Goggi *et al.*, 2003). In fact, direct activity-dependent pre- to post-synaptic transneuronal transfer of BDNF has recently been demonstrated using fluorescently-labelled BDNF (Kohara *et al.*, 2001). The released form of BDNF is thought to be proBDNF (Mowla *et al.*, 2001), raising the possibility of postsecretory proteolytic processing by membrane-associated or extracellular proteases in the modulation of BDNF action (Lee *et al.*, 2001a,b).

BDNF AND DEVELOPMENT

BDNF has survival- and growth-promoting actions on a variety of neurons, including dorsal root ganglion cells (Acheson *et al.*, 1995) and hippocampal and cortical neurons (Huang and Reichardt, 2001). Certain peripheral sensory neurons, especially those in vestibular and nodose-petrosal ganglia, depend on the presence of BDNF because

BDNF homozygous ($-/-$) knockout mice lack these neurons (Huang and Reichardt, 2001). Unlike NGF, sympathetic neurons are not affected, nor are motor neurons. BDNF homozygous ($-/-$) knockout mice fail to survive past 3 weeks, but heterozygous BDNF knockout ($+/-$) mice are viable, and exhibit a variety of phenotypes, including obesity (Lyons *et al.*, 1999; Kerner *et al.*, 2000), decreased seizure susceptibility (Kokaia *et al.*, 1995) and impaired spatial learning (Linnarsson *et al.*, 1997). Interestingly, conditional postnatal BDNF gene deletion (Rios *et al.*, 2001) and reduction in trkB expression (Xu *et al.*, 2003) also cause obesity.

Physiologic regulation of BDNF gene expression may be very important in the development of the brain. For example, BDNF contributes to activity-dependent development of the visual cortex. Provision of excess BDNF (Cabelli *et al.*, 1995) or blockade of BDNF signalling (Cabelli *et al.*, 1997) leads to abnormal patterning of ocular dominance columns during a critical

period of visual cortex development. This suggests a role for BDNF in axonal path-finding during development. BDNF also has powerful effects on dendritic morphology (McAllister *et al.*, 1997; Murphy *et al.*, 1998; Horch and Katz, 2002; Tolwani *et al.*, 2002).

EFFECTS ON SYNAPTIC TRANSMISSION

The first studies of BDNF effects on synaptic transmission showed that BDNF increased the frequency of miniature excitatory postsynaptic currents (EPSCs) in *Xenopus* cultures (Lohof *et al.*, 1993). Since then, numerous studies have examined the actions of BDNF. Overall, BDNF appears to strengthen excitatory (glutamatergic) synapses and weaken inhibitory (GABAergic) synapses. Schuman and colleagues demonstrated that exposure of adult rat hippocampal slices to BDNF led to a long-lasting potentiation of afferent input to hippocampal pyramidal cells (Kang and Schuman, 1995). Subsequent studies have supported a role of BDNF in LTP (Korte *et al.*, 1995, 1996; Patterson *et al.*, 1996; Kang, 1997; Xu *et al.*, 2003). For example, incubation of hippocampal or visual cortical slices with trkB inhibitors inhibits LTP (Figurov *et al.*, 1996), and hippocampal slices from BDNF knockout animals exhibit impaired LTP induction (Korte *et al.*, 1995) which is restored by reintroduction of BDNF (Korte *et al.*, 1996; Patterson *et al.*, 1996).

Whether BDNF-induced synaptic potentiation occurs primarily by a presynaptic action (e.g. through enhancement of glutamate release) or postsynaptically (e.g. via phosphorylation of neurotransmitter receptors) is intensely debated (Schinder and Poo, 2000) (Fig. 1). A number of studies have provided evidence for a presynaptic locus (Xu *et al.*, 2000; Tyler *et al.*, 2002) (see also, Kafitz *et al.* (1999)), yet evidence for postsynaptic actions has also been obtained (Black, 1999; Thakker-Varia *et al.*, 2001) (reviewed in Poo (2001)). Both pre- and postsynaptic trkB receptors in the hippocampus may be important (Drake *et al.*, 1999).

A role for BDNF in GABAergic synapses was first raised by studies showing that BDNF influences GABAergic neuronal phenotype (Marty *et al.*, 1996). Subsequently, BDNF was shown to decrease inhibitory (GABAergic) synaptic transmission (Tanaka *et al.*, 1997; Frerking *et al.*, 1998; Wardle and Poo, 2003), perhaps in part via modulation of GABA_A receptor phosphorylation (Jovanovic *et al.*, 2004). Interestingly, BDNF may also regulate the efficacy of GABAergic synapses by direct downregulation of the neuronal K⁺-Cl⁻ co-transporter, which would impair neuronal Cl⁻ extrusion and weaken GABAergic inhibition (Rivera *et al.*, 2002). Similarly, a recent paper found differential effects of BDNF on GABA-mediated currents in excitatory and inhibitory neuron subpopulations, selectively decreasing the efficacy of inhibitory neurotransmission by downregulation of Cl⁻ transport (Wardle and Poo, 2003).

NEUROGENESIS

BDNF has also been found to enhance neurogenesis. For example, intraventricular infusion of BDNF or adenoviral-induced BDNF activity increases the number of neurons in the adult olfactory bulb, striatum, septum and thalamus (Zigova *et al.*, 1998; Benraiss *et al.*, 2001; Pencea *et al.*, 2001), which can be potentiated by concurrent inhibition of glial differentiation of subependymal progenitor cells (Chmielnicki *et al.*, 2004). Studies of cultured progenitor cells have elucidated some of the signalling mechanisms, which appear to involve trkB activation, followed by activation of the MAP kinase and PI3-kinase pathways (Barnabe-Heider and Miller, 2003) and downstream modification of basic helix-loop-helix transcription factors (Ito *et al.*, 2003). Although some studies have concluded that the primary effect of BDNF is on proliferation (Kato-Semba *et al.*, 2002), other experiments suggest an important effect on survival (Lee *et al.*, 2002). The effects of BDNF may depend on a previous history of ischemic damage (Larsson *et al.*, 2002; Gustafsson *et al.*, 2003).

LEARNING AND MEMORY

Since BDNF appears to be involved in activity-dependent synaptic plasticity, there is great interest in its role in learning and memory (Yamada and Nabeshima, 2003). The hippocampus, which is required for many forms of long-term memory in humans and animals, appears to be an important site of BDNF action. Rapid and selective induction of BDNF expression in the hippocampus during contextual learning has been demonstrated (Hall *et al.*, 2000), and function-blocking antibodies to BDNF (Alonso *et al.*, 2002), BDNF knockout (Linnarsson *et al.*, 1997), knockout of forebrain trkB signalling (Minichiello *et al.*, 1999), or overexpression of truncated trkB (Saarelainen *et al.*, 2000a,b) in mice impairs spatial learning. Another study demonstrated upregulation of BDNF in monkey parietal cortex associated with tool-use learning (Ishibashi *et al.*, 2002). In humans, a valine to methionine polymorphism at the 5' pro-region of the human BDNF protein was found to be associated with poorer episodic memory; *in vitro*, neurons transfected with met-BDNF-GFP exhibited reduced depolarization-induced BDNF secretion (Egan *et al.*, 2003).

BDNF AND EPILEPSY

The discovery that limbic seizures increase NGF mRNA levels (Gall and Isackson, 1989) led to the idea that seizure-induced expression of neurotrophic factors may contribute to the lasting structural and functional changes underlying epileptogenesis (Gall *et al.*, 1991; 1997; Jankowsky and Patterson, 2001). Recent *in vitro*

and *in vivo* findings implicate BDNF in the cascade of electrophysiologic and behavioural changes underlying the epileptic state. BDNF mRNA and protein are markedly upregulated in the hippocampus by seizure activity in animal models (Ernfors *et al.*, 1991; Isackson *et al.*, 1991; Lindvall *et al.*, 1994; Nibuya *et al.*, 1995), and infusion of anti-BDNF agents (Binder *et al.*, 1999b) or use of BDNF knockout (Kokaia *et al.*, 1995) or truncated trkB-overexpressing (Lahteinen *et al.*, 2002) mice inhibits epileptogenesis in animal models. Conversely, direct application of BDNF induces hyperexcitability *in vitro* (Scharfman, 1997; Scharfman *et al.*, 1999), overexpression of BDNF in transgenic mice leads to spontaneous seizures (Croll *et al.*, 1999), and intrahippocampal infusion of BDNF is sufficient to induce seizure activity *in vivo* (Scharfman *et al.*, 2002) (but see, Reibel *et al.* (2000)). The hippocampus and closely associated limbic structures are thought to be particularly important in the pro-epileptogenic effects of BDNF (Binder *et al.*, 1999a,b), and indeed increased BDNF expression in the hippocampus is found in specimens from patients with temporal lobe epilepsy (Mathern *et al.*, 1997; Takahashi *et al.*, 1999). It is hoped that understanding of the hyperexcitability associated with BDNF in epilepsy animal models may lead to novel anticonvulsant or antiepileptogenic therapies (Binder *et al.*, 2001).

BDNF AND PAIN

BDNF also may play an important neuromodulatory role in pain transduction (Malcangio and Lessmann, 2003). BDNF is synthesized by dorsal horn neurons and markedly upregulated in inflammatory injury to peripheral nerves (along with NGF) (Fukuoka *et al.*, 2001). BDNF acutely sensitizes nociceptive afferents and elicits hyperalgesia which is abrogated by BDNF inhibitors (Kerr *et al.*, 1999; Thompson *et al.*, 1999; Pezet *et al.*, 2002). Central pain sensitization is an activity-dependent increase in excitability of dorsal horn neurons leading to a clinically intractable condition termed “neuropathic pain” in which normally nonpainful somatosensory stimuli (touch and pressure) become exquisitely painful (allodynia). Electrophysiological and behavioural data demonstrate that inhibition of BDNF signal transduction inhibits central pain sensitization (Kerr *et al.*, 1999; Pezet *et al.*, 2002).

BDNF AND NEURODEGENERATIVE DISEASES

The idea that degenerative diseases of the nervous system may result from insufficient supply of neurotrophic factors has generated great interest in BDNF as a potential therapeutic agent. Many reports have documented evidence of decreased expression of BDNF in neurological disease (Murer *et al.*, 2001). Selective

reduction of BDNF mRNA in the hippocampus has been reported in Alzheimer’s disease specimens (Phillips *et al.*, 1991; Ferrer *et al.*, 1999), although in an animal model upregulation appears to occur in plaque-related glial cells (Burbach *et al.*, 2004). Decreased BDNF protein has been demonstrated in the substantia nigra in Parkinson’s disease (Howells *et al.*, 2000). Interestingly, recent work has implicated BDNF in Huntington’s disease as well. Huntingtin, the protein mutated in Huntington’s disease, upregulates BDNF transcription, and loss of huntingtin-mediated BDNF transcription leads to loss of trophic support to striatal neurons which subsequently degenerate in the hallmark pathology of the disorder (Zuccato *et al.*, 2001). A recent study has demonstrated that huntingtin normally inhibits the neuron restrictive silencer element (NRSE) involved in tonic repression of transcription from BDNF promoter II (Zuccato *et al.*, 2003). In all of these disorders, provision of BDNF or increasing endogenous BDNF production may conceivably be therapeutic if applied in the appropriate spatiotemporal context (Spires *et al.*, 2004).

BDNF AND NEUROPSYCHIATRIC DISEASE

BDNF signalling may also be involved in affective behaviours (Altar, 1999). Environmental stresses such as immobilization that induce depression also decrease BDNF mRNA (Smith *et al.*, 1995). Conversely, physical exercise is associated with decreased depression and increased BDNF mRNA (Russo-Neustadt *et al.*, 1999; Cotman and Berchtold, 2002). Existing treatments for depression are thought to act primarily by increasing endogenous monoaminergic (*i.e.* serotonergic and noradrenergic) synaptic transmission, and recent studies have shown that effective antidepressants increase BDNF mRNA (Dias *et al.*, 2003) and protein (Chen *et al.*, 2001; Altar *et al.*, 2003). Exogenous delivery of BDNF promotes the function and sprouting of serotonergic neurons in adult rat brains (Mamounas *et al.*, 1995), and BDNF-deficient mice are also deficient in serotonergic innervation (Lyons *et al.*, 1999). Thus, new pharmacologic strategies are focused on the potential antidepressant role of BDNF.

It has also been hypothesized that BDNF may be involved in bipolar disorder (Tsai, 2004). Interestingly, lithium, a major drug for the treatment of bipolar disorder, increases BDNF and trkB activation in cerebral cortical neurons (Hashimoto *et al.*, 2002). BDNF is an attractive candidate gene for susceptibility to bipolar disorder, and some (Neves-Pereira *et al.*, 2002; Sklar *et al.*, 2002) but not other (Hong *et al.*, 2003; Nakata *et al.*, 2003) studies suggest linkage between BDNF polymorphisms and disease susceptibility (Green and Craddock, 2003). How alterations in BDNF activity may relate to fluctuating bouts of mania and depression in bipolar disorder is still a matter of speculation.

SUMMARY

Since the purification of BDNF in 1982, a great deal of evidence has mounted for its central roles in brain development, physiology, and pathology. Aside from its importance in neural development and cell survival, BDNF appears essential to molecular mechanisms of synaptic plasticity. Basic activity-related changes in the central nervous system are thought to depend on BDNF modification of synaptic transmission, especially in the hippocampus and neocortex. Pathologic levels of BDNF-dependent synaptic plasticity may contribute to conditions such as epilepsy and chronic pain sensitization, whereas application of the trophic properties of BDNF may lead to novel therapeutic options in neurodegenerative diseases and perhaps even in neuropsychiatric disorders.

References

- Acheson, A., *et al.* (1995) "A BDNF autocrine loop in adult sensory neurons prevents cell death", *Nature* **374**, 450–453.
- Alderson, R.F., *et al.* (2000) "Truncated TrkB mediates the endocytosis and release of BDNF and neurotrophin-4/5 by rat astrocytes and schwann cells *in vitro*", *Brain Res.* **871**, 210–222.
- Alonso, M., *et al.* (2002) "BDNF-triggered events in the rat hippocampus are required for both short- and long-term memory formation", *Hippocampus* **12**, 551–560.
- Altar, C.A. (1999) "Neurotrophins and depression", *Trends Pharmacol. Sci.* **20**, 59–61.
- Altar, C.A. and DiStefano, P.S. (1998) "Neurotrophin trafficking by anterograde transport", *Trends Neurosci.* **21**, 433–437.
- Altar, C.A., *et al.* (1997) "Anterograde transport of brain-derived neurotrophic factor and its role in the brain", *Nature* **389**, 856–860.
- Altar, C.A., *et al.* (2003) "Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain", *Biol. Psychiatry* **54**, 703–709.
- Barbacid, M. (1994) "The Trk family of neurotrophin receptors", *J. Neurobiol.* **25**, 1386–1403.
- Barde, Y.A., Edgar, D. and Thoenen, H. (1982) "Purification of a new neurotrophic factor from mammalian brain", *EMBO J.* **1**, 549–553.
- Barnabe-Heider, F. and Miller, F.D. (2003) "Endogenously produced neurotrophins regulate survival and differentiation of cortical progenitors via distinct signaling pathways", *J. Neurosci.* **23**, 5149–5160.
- Benraiss, A., *et al.* (2001) "Adenoviral brain-derived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain", *J. Neurosci.* **21**, 6718–6731.
- Biffo, S., *et al.* (1995) "Selective binding and internalisation by truncated receptors restrict the availability of BDNF during development", *Development* **121**, 2461–2470.
- Binder, D.K., Routbort, M.J. and McNamara, J.O. (1999a) "Immunohistochemical evidence of seizure-induced activation of trk receptors in the mossy fiber pathway of adult rat hippocampus", *J. Neurosci.* **19**, 4616–4626.
- Binder, D.K., *et al.* (1999b) "Selective inhibition of kindling development by intraventricular administration of TrkB receptor body", *J. Neurosci.* **19**, 1424–1436.
- Binder, D.K., *et al.* (2001) "BDNF and epilepsy: too much of a good thing?", *Trends Neurosci.* **24**, 47–53.
- Black, I.B. (1999) "Trophic regulation of synaptic plasticity", *J. Neurobiol.* **41**, 108–118.
- Bramham, C.R., *et al.* (1996) "Unilateral LTP triggers bilateral increases in hippocampal neurotrophin and trk receptor mRNA expression in behaving rats: evidence for interhemispheric communication", *J. Comp. Neurol.* **368**, 371–382.
- Bregola, G., *et al.* (2000) "Different patterns of induction of fibroblast growth factor-2 and brain-derived neurotrophic factor messenger RNAs during kindling epileptogenesis, and development of a herpes simplex vector for fibroblast growth factor-2 gene transfer *in vivo*", *Epilepsia* **41**(Suppl. 6), S122–S126.
- Burbach, G.J., *et al.* (2004) "Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice", *J. Neurosci.* **24**, 2421–2430.
- Cabelli, R.J., Hohn, A. and Shatz, C.J. (1995) "Inhibition of ocular dominance column formation by infusion of NT-4/5 or BDNF", *Science* **267**, 1662–1666.
- Cabelli, R.J., *et al.* (1997) "Blockade of endogenous ligands of trkB inhibits formation of ocular dominance columns", *Neuron* **19**, 63–76.
- Casaccia-Bonnet, P., *et al.* (1996) "Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75", *Nature* **383**, 716–719.
- Castrén, E., *et al.* (1992) "Light regulates expression of brain-derived neurotrophic factor mRNA in rat visual cortex", *Proc. Natl Acad. Sci. USA* **89**, 9444–9448.
- Castrén, E., *et al.* (1993) "The induction of LTP increases BDNF and NGF mRNA but decreases NT-3 mRNA in the dentate gyrus", *Neuroreport* **4**, 895–898.
- Castrén, E., Thoenen, H. and Lindholm, D. (1995) "Brain-derived neurotrophic factor messenger RNA is expressed in the septum, hypothalamus and in adrenergic brain stem nuclei of adult rat brain and is increased by osmotic stimulation in the paraventricular nucleus", *Neuroscience* **64**, 71–80.
- Castrén, E., *et al.* (1998) "Regulation of brain-derived neurotrophic factor mRNA levels in hippocampus by neuronal activity", *Prog. Brain Res.* **117**, 57–64.
- Chao, M.V. and Hempstead, B.L. (1995) "p75 and Trk: a two-receptor system", *Trends Neurosci.* **18**, 321–326.
- Chao, M.V. and Bothwell, M. (2002) "Neurotrophins: to cleave or not to cleave", *Neuron* **33**, 9–12.
- Chen, B., *et al.* (2001) "Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication", *Biol. Psychiatry* **50**, 260–265.
- Chen, W.G., *et al.* (2003) "Depression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2", *Science* **302**, 885–889.
- Chmielnicki, E., *et al.* (2004) "Adenovirally expressed noggin and brain-derived neurotrophic factor cooperate to induce new medium spiny neurons from resident progenitor cells in the adult striatal ventricular zone", *J. Neurosci.* **24**, 2133–2142.
- Climent, E. (2000) "Astrocytes in culture express the full-length Trk-B receptor and respond to brain derived neurotrophic factor by changing intracellular calcium levels: effect of ethanol exposure in rats", *Neurosci. Lett.* **288**, 53–56.
- Conner, J.M., *et al.* (1997) "Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport", *J. Neurosci.* **17**, 2295–2313.
- Cotman, C.W. and Berchtold, N.C. (2002) "Exercise: a behavioral intervention to enhance brain health and plasticity", *Trends Neurosci.* **25**, 295–301.
- Croll, S.D., *et al.* (1999) "Brain-derived neurotrophic factor transgenic mice exhibit passive avoidance deficits, increased seizure severity and *in vitro* hyperexcitability in the hippocampus and entorhinal cortex", *Neuroscience* **93**, 1491–1506.
- Dechant, G. and Barde, Y.A. (2002) "The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system", *Nat. Neurosci.* **5**, 1131–1136.
- Dias, B.G., *et al.* (2003) "Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain", *Neuropharmacology* **45**, 553–563.
- Drake, C.T., Milner, T.A. and Patterson, S.L. (1999) "Ultrastructural localization of full-length trkB immunoreactivity in rat hippocampus suggests multiple roles in modulating activity-dependent synaptic plasticity", *J. Neurosci.* **19**, 8009–8026.
- Egan, M.F., *et al.* (2003) "The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function", *Cell* **112**, 257–269.
- Eide, F.F., *et al.* (1996) "Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling", *J. Neurosci.* **16**, 3123–3129.
- Ernfors, P., *et al.* (1991) "Increased levels of messenger RNAs for neurotrophic factors in the brain during kindling epileptogenesis", *Neuron* **7**, 165–176.

- Esposito, D., *et al.* (2001) "The cytoplasmic and transmembrane domains of the p75 and Trk A receptors regulate high affinity binding to nerve growth factor", *J. Biol. Chem.* **276**, 32687–32695.
- Farhadi, H.F., *et al.* (2000) "Neurotrophin-3 sorts to the constitutive secretory pathway of hippocampal neurons and is diverted to the regulated secretory pathway by coexpression with brain-derived neurotrophic factor", *J. Neurosci.* **20**, 4059–4068.
- Fawcett, J.P., *et al.* (1997) "Detection of brain-derived neurotrophic factor in a vesicular fraction of brain synaptosomes", *J. Biol. Chem.* **272**, 8837–8840.
- Fawcett, J.P., *et al.* (1998) "Functional evidence that BDNF is an anterograde neuronal trophic factor in the CNS", *J. Neurosci.* **18**, 2808–2821.
- Fawcett, J.P., *et al.* (2000) "Evidence that brain-derived neurotrophic factor from presynaptic nerve terminals regulates the phenotype of calbindin-containing neurons in the lateral septum", *J. Neurosci.* **20**, 274–282.
- Ferrer, I., *et al.* (1999) "BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies", *J. Neuropathol. Exp. Neurol.* **58**, 729–739.
- Figurov, A., *et al.* (1996) "Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus", *Nature* **381**, 706–709.
- Frade, J.M., Rodriguez-Tebar, A. and Barde, Y.A. (1996) "Induction of cell death by endogenous nerve growth factor through its p75 receptor", *Nature* **383**, 166–168.
- Frerking, M., Malenka, R.C. and Nicoll, R.A. (1998) "Brain-derived neurotrophic factor (BDNF) modulates inhibitory, but not excitatory, transmission in the CA1 region of the hippocampus", *J. Neurophysiol.* **80**, 3383–3386.
- Frisen, J., *et al.* (1993) "Characterization of glial trkB receptors: differential response to injury in the central and peripheral nervous systems", *Proc. Natl Acad. Sci. USA* **90**, 4971–4975.
- Fryer, R.H., Kaplan, D.R. and Kromer, L.F. (1997) "Truncated trkB receptors on nonneuronal cells inhibit BDNF-induced neurite outgrowth *in vitro*", *Exp. Neurol.* **148**, 616–627.
- Fukuoka, T., *et al.* (2001) "Brain-derived neurotrophic factor increases in the uninjured dorsal root ganglion neurons in selective spinal nerve ligation model", *J. Neurosci.* **21**, 4891–4900.
- Gall, C.M. and Isackson, P.J. (1989) "Limbic seizures increase neuronal production of messenger RNA for nerve growth factor", *Science* **245**, 758–761.
- Gall, C., *et al.* (1991) "Seizures and the regulation of neurotrophic factor and neuropeptide gene expression in brain", *Epilepsy Res. Suppl.* **4**, 225–245.
- Gall, C.M., *et al.* (1997) "Seizures and the regulation of neurotrophic factor expression: associations with structural plasticity in epilepsy", *Adv. Neurol.* **72**, 9–24.
- Ginty, D.D. and Segal, R.A. (2002) "Retrograde neurotrophin signaling: Trk-ing along the axon", *Curr. Opin. Neurobiol.* **12**, 268–274.
- Goggi, J., *et al.* (2003) "The control of [125I]BDNF release from striatal rat brain slices", *Brain Res.* **967**, 201–209.
- Green, E. and Craddock, N. (2003) "Brain-derived neurotrophic factor as a potential risk locus for bipolar disorder: evidence, limitations, and implications", *Curr. Psychiatry Rep.* **5**, 469–476.
- Griesbeck, O., *et al.* (1999) "Are there differences between the secretion characteristics of NGF and BDNF? Implications for the modulatory role of neurotrophins in activity-dependent neuronal plasticity", *Microsc. Res. Tech.* **45**, 262–275.
- Gustafsson, E., Lindvall, O. and Kokaia, Z. (2003) "Intraventricular infusion of TrkB-Fc fusion protein promotes ischemia-induced neurogenesis in adult rat dentate gyrus", *Stroke* **34**, 2710–2715.
- Haapasalo, A., *et al.* (2001) "Truncated trkB.T1 is dominant negative inhibitor of trkB. TK + -mediated cell survival", *Biochem. Biophys. Res. Commun.* **280**, 1352–1358.
- Haapasalo, A., *et al.* (2002) "Regulation of TRKB surface expression by brain-derived neurotrophic factor and truncated TRKB isoforms", *J. Biol. Chem.* **277**, 43160–43167.
- Hall, J., Thomas, K.L. and Everitt, B.J. (2000) "Rapid and selective induction of BDNF expression in the hippocampus during contextual learning", *Nat. Neurosci.* **3**, 533–535.
- Hallbook, F., Ibanez, C.F. and Persson, H. (1991) "Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in *Xenopus* ovary", *Neuron* **6**, 845–858.
- Hashimoto, R., *et al.* (2002) "Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity", *Neuropharmacology* **43**, 1173–1179.
- Hong, C.J., *et al.* (2003) "Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior", *Neuropsychobiology* **48**, 186–189.
- Horch, H.W. and Katz, L.C. (2002) "BDNF release from single cells elicits local dendritic growth in nearby neurons", *Nat. Neurosci.* **5**, 1177–1184.
- Howells, D.W., *et al.* (2000) "Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra", *Exp. Neurol.* **166**, 127–135.
- Huang, E.J. and Reichardt, L.F. (2001) "Neurotrophins: roles in neuronal development and function", *Annu. Rev. Neurosci.* **24**, 677–736.
- Ip, N.Y., *et al.* (1992) "Mammalian neurotrophin-4: structure, chromosomal localization, tissue distribution, and receptor specificity", *Proc. Natl Acad. Sci. USA* **89**, 3060–3064.
- Isackson, P.J., *et al.* (1991) "BDNF mRNA expression is increased in adult rat forebrain after limbic seizures: temporal patterns of induction distinct from NGF", *Neuron* **6**, 937–948.
- Ishibashi, H., *et al.* (2002) "Tool-use learning induces BDNF expression in a selective portion of monkey anterior parietal cortex", *Brain Res. Mol. Brain Res.* **102**, 110–112.
- Ito, H., *et al.* (2003) "Neurotrophins facilitate neuronal differentiation of cultured neural stem cells via induction of mRNA expression of basic helix-loop-helix transcription factors Mash1 and Math1", *J. Neurosci. Res.* **71**, 648–658.
- Jankowsky, J.L. and Patterson, P.H. (2001) "The role of cytokines and growth factors in seizures and their sequelae", *Prog. Neurobiol.* **63**, 125–149.
- Jovanovic, J.N., *et al.* (2004) "Brain-derived neurotrophic factor modulates fast synaptic inhibition by regulating GABA(A) receptor phosphorylation, activity, and cell-surface stability", *J. Neurosci.* **24**, 522–530.
- Kafitz, K.W., *et al.* (1999) "Neurotrophin-evoked rapid excitation through TrkB receptors", *Nature* **401**, 918–921.
- Kang, H. and Schuman, E.M. (1995) "Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus", *Science* **267**, 1658–1662.
- Kang, H., *et al.* (1997) "Neurotrophins and time: different roles for TrkB signaling in hippocampal long-term potentiation", *Neuron* **19**, 653–664.
- Kato-Semba, R., *et al.* (2002) "Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus", *FASEB J.* **16**, 1328–1330.
- Kernie, S.G., Liebl, D.J. and Parada, L.F. (2000) "BDNF regulates eating behavior and locomotor activity in mice", *EMBO J.* **19**, 1290–1300.
- Kerr, B.J., *et al.* (1999) "Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord", *J. Neurosci.* **19**, 5138–5148.
- Kohara, K., *et al.* (2001) "Activity-dependent transfer of brain-derived neurotrophic factor to postsynaptic neurons", *Science* **291**, 2419–2423.
- Kokaia, M., *et al.* (1995) "Suppressed epileptogenesis in BDNF mutant mice", *Exp. Neurol.* **133**, 215–224.
- Korte, M., *et al.* (1995) "Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor", *Proc. Natl Acad. Sci. USA* **92**, 8856–8860.
- Korte, M., *et al.* (1996) "Virus-mediated gene transfer into hippocampal CA1 region restores long-term potentiation in brain-derived neurotrophic factor mutant mice", *Proc. Natl Acad. Sci. USA* **93**, 12547–12552.
- Lahtinen, S., *et al.* (2002) "Decreased BDNF signalling in transgenic mice reduces epileptogenesis", *Eur. J. Neurosci.* **15**, 721–734.
- Larsson, E., *et al.* (2002) "Suppression of insult-induced neurogenesis in adult rat brain by brain-derived neurotrophic factor", *Exp. Neurol.* **177**, 1–8.
- Lauterborn, J.C., *et al.* (1996) "Differential effects of protein synthesis inhibition on the activity-dependent expression of BDNF transcripts: evidence for immediate-early gene responses from specific promoters", *J. Neurosci.* **16**, 7428–7436.
- Lee, F.S., *et al.* (2001a) "The uniqueness of being a neurotrophin receptor", *Curr. Opin. Neurobiol.* **11**, 281–286.
- Lee, R., *et al.* (2001b) "Regulation of cell survival by secreted proneurotrophins", *Science* **294**, 1945–1948.
- Lee, J., Duan, W. and Mattson, M.P. (2002) "Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice", *J. Neurochem.* **82**, 1367–1375.

- Levi-Montalcini, R. and Hamburger, V. (1951) "Selective growth-stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo", *J. Exp. Zool.* **116**, 321–361.
- Lindholm, D., et al. (1994) "Activity-dependent and hormonal regulation of neurotrophin mRNA levels in the brain—implications for neuronal plasticity", *J. Neurobiol.* **25**, 1362–1372.
- Lindvall, O., et al. (1994) "Neurotrophins and brain insults", *Trends Neurosci.* **17**, 490–496.
- Linnarsson, S., Bjorklund, A. and Ernfors, P. (1997) "Learning deficit in BDNF mutant mice", *Eur. J. Neurosci.* **9**, 2581–2587.
- Lohof, A.M., Ip, N.Y. and Poo, M.M. (1993) "Potentiation of developing neuromuscular synapses by the neurotrophins NT-3 and BDNF", *Nature* **363**, 350–353.
- Luikart, B.W., et al. (2003) "In vivo role of truncated trkB receptors during sensory ganglion neurogenesis", *Neuroscience* **117**, 847–858.
- Lyons, W.E., et al. (1999) "Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities", *Proc. Natl Acad. Sci. USA* **96**, 15239–15244.
- Maisonpierre, P.C., et al. (1990) "Neurotrophin-3: a neurotrophic factor related to NGF and BDNF", *Science* **247**, 1446–1451.
- Malcangio, M. and Lessmann, V. (2003) "A common thread for pain and memory synapses? Brain-derived neurotrophic factor and trkB receptors", *Trends Pharmacol. Sci.* **24**, 116–121.
- Mamounas, L.A., et al. (1995) "Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain", *J. Neurosci.* **15**, 7929–7939.
- Marty, S., et al. (1996) "GABAergic stimulation regulates the phenotype of hippocampal interneurons through the regulation of brain-derived neurotrophic factor", *Neuron* **16**, 565–570.
- Mathern, G.W., et al. (1997) "Granule cell mRNA levels for BDNF, NGF, and NT-3 correlate with neuron losses or supragranular mossy fiber sprouting in the chronically damaged and epileptic human hippocampus", *Mol. Chem. Neuropathol.* **30**, 53–76.
- McAllister, A.K., Katz, L.C. and Lo, D.C. (1997) "Opposing roles for endogenous BDNF and NT-3 in regulating cortical dendritic growth", *Neuron* **18**, 767–778.
- Merlio, J.P., et al. (1993) "Increased production of the trkB protein tyrosine kinase receptor after brain insults", *Neuron* **10**, 151–164.
- Metsis, M., et al. (1993) "Differential usage of multiple brain-derived neurotrophic factor promoters in the rat brain following neuronal activation", *Proc. Natl Acad. Sci. USA* **90**, 8802–8806.
- Miller, F.D. and Kaplan, D.R. (2001) "On Trk for retrograde signaling", *Neuron* **32**, 767–770.
- Minichiello, L., et al. (1999) "Essential role for TrkB receptors in hippocampus-mediated learning", *Neuron* **24**, 401–414.
- Mowla, S.J., et al. (1999) "Differential sorting of nerve growth factor and brain-derived neurotrophic factor in hippocampal neurons", *J. Neurosci.* **19**, 2069–2080.
- Mowla, S.J., et al. (2001) "Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor", *J. Biol. Chem.* **276**, 12660–12666.
- Murer, M.G., Yan, Q. and Raisman-Vozari, R. (2001) "Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease", *Prog. Neurobiol.* **63**, 71–124.
- Murphy, D.D., Cole, N.B. and Segal, M. (1998) "Brain-derived neurotrophic factor mediates estradiol-induced dendritic spine formation in hippocampal neurons", *Proc. Natl Acad. Sci. USA* **95**, 11412–11417.
- Nakata, K., et al. (2003) "Association study of the brain-derived neurotrophic factor (BDNF) gene with bipolar disorder", *Neurosci. Lett.* **337**, 17–20.
- Neeper, S.A., et al. (1995) "Exercise and brain neurotrophins", *Nature* **373**, 109.
- Neves-Pereira, M., et al. (2002) "The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study", *Am. J. Hum. Genet.* **71**, 651–655.
- Nibuya, M., Morinobu, S. and Duman, R.S. (1995) "Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments", *J. Neurosci.* **15**, 7539–7547.
- Nibuya, M., Nestler, E.J. and Duman, R.S. (1996) "Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus", *J. Neurosci.* **16**, 2365–2372.
- Patapoutian, A. and Reichardt, L.F. (2001) "Trk receptors: mediators of neurotrophin action", *Curr. Opin. Neurobiol.* **11**, 272–280.
- Patterson, S.L., et al. (1992) "Neurotrophin expression in rat hippocampal slices: a stimulus paradigm inducing LTP in CA1 evokes increases in BDNF and NT-3 mRNAs", *Neuron* **9**, 1081–1088.
- Patterson, S.L., et al. (1996) "Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice", *Neuron* **16**, 1137–1145.
- Pencea, V., et al. (2001) "Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus", *J. Neurosci.* **21**, 6706–6717.
- Pezet, S., et al. (2002) "Noxious stimulation induces Trk receptor and downstream ERK phosphorylation in spinal dorsal horn", *Mol. Cell. Neurosci.* **21**, 684–695.
- Phillips, H.S., et al. (1991) "BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease", *Neuron* **7**, 695–702.
- Poo, M.M. (2001) "Neurotrophins as synaptic modulators", *Nat. Rev. Neurosci.* **2**, 24–32.
- Reibel, S., et al. (2000) "Brain-derived neurotrophic factor delays hippocampal kindling in the rat", *Neuroscience* **100**, 777–788.
- Rios, M., et al. (2001) "Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity", *Mol. Endocrinol.* **15**, 1748–1757.
- Rivera, C., et al. (2002) "BDNF-induced TrkB activation down-regulates the K⁺–Cl[–] cotransporter KCC2 and impairs neuronal Cl[–] extrusion", *J. Cell Biol.* **159**, 747–752.
- Roback, J.D., et al. (1995) "BDNF-activated signal transduction in rat cortical glial cells", *Eur. J. Neurosci.* **7**, 849–862.
- Rocamora, N., et al. (1996) "Upregulation of BDNF mRNA expression in the barrel cortex of adult mice after sensory stimulation", *J. Neurosci.* **16**, 4411–4419.
- Rose, C.R., et al. (2003) "Truncated TrkB-T1 mediates neurotrophin-evoked calcium signalling in glia cells", *Nature* **426**, 74–78.
- Roux, P.P., et al. (1999) "p75 neurotrophin receptor expression is induced in apoptotic neurons after seizure", *J. Neurosci.* **19**, 6887–6896.
- Russo-Neustadt, A., Beard, R.C. and Cotman, C.W. (1999) "Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression", *Neuropsychopharmacology* **21**, 679–682.
- Saarelainen, T., et al. (2000a) "Transgenic mice overexpressing truncated trkB neurotrophin receptors in neurons show increased susceptibility to cortical injury after focal cerebral ischemia", *Mol. Cell Neurosci.* **16**, 87–96.
- Saarelainen, T., et al. (2000b) "Transgenic mice overexpressing truncated trkB neurotrophin receptors in neurons have impaired long-term spatial memory but normal hippocampal LTP", *Synapse* **38**, 102–104.
- Scharfman, H.E. (1997) "Hyperexcitability in combined entorhinal/hippocampal slices of adult rat after exposure to brain-derived neurotrophic factor", *J. Neurophysiol.* **78**, 1082–1095.
- Scharfman, H.E., Goodman, J.H. and Sollas, A.L. (1999) "Actions of brain-derived neurotrophic factor in slices from rats with spontaneous seizures and mossy fiber sprouting in the dentate gyrus", *J. Neurosci.* **19**, 5619–5631.
- Scharfman, H.E., et al. (2002) "Spontaneous limbic seizures after intrahippocampal infusion of brain-derived neurotrophic factor", *Exp. Neurol.* **174**, 201–214.
- Scharfman, H.E., et al. (2003) "Hippocampal excitability increases during the estrous cycle in the rat: a potential role for brain-derived neurotrophic factor", *J. Neurosci.* **23**, 11641–11652.
- Schinder, A.F. and Poo, M. (2000) "The neurotrophin hypothesis for synaptic plasticity", *Trends Neurosci.* **23**, 639–645.
- Segal, R.A. (2003) "Selectivity in neurotrophin signaling: theme and variations", *Annu. Rev. Neurosci.* **26**, 299–330.
- Shieh, P.B. and Ghosh, A. (1999) "Molecular mechanisms underlying activity-dependent regulation of BDNF expression", *J. Neurobiol.* **41**, 127–134.
- Shieh, P.B., et al. (1998) "Identification of a signaling pathway involved in calcium regulation of BDNF expression", *Neuron* **20**, 727–740.
- Simonato, M., et al. (2002) "Dendritic targeting of mRNAs for plasticity genes in experimental models of temporal lobe epilepsy", *Epilepsia* **43**(Suppl. 5), 153–158.
- Sklar, P., et al. (2002) "Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neurotrophic factor", *Mol. Psychiatry* **7**, 579–593.

- Smith, M.A., *et al.* (1995) "Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus", *J. Neurosci.* **15**, 1768–1777.
- Spires, T.L., *et al.* (2004) "Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism", *J. Neurosci.* **24**, 2270–2276.
- Takahashi, M., *et al.* (1999) "Patients with temporal lobe epilepsy show an increase in brain-derived neurotrophic factor protein and its correlation with neuropeptide Y", *Brain Res.* **818**, 579–582.
- Tanaka, T., Saito, H. and Matsuki, N. (1997) "Inhibition of GABAA synaptic responses by brain-derived neurotrophic factor (BDNF) in rat hippocampus", *J. Neurosci.* **17**, 2959–2966.
- Tao, X., *et al.* (1998) "Ca²⁺ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism", *Neuron* **20**, 709–726.
- Tao, X., *et al.* (2002) "A calcium-responsive transcription factor, CaRF, that regulates neuronal activity-dependent expression of BDNF", *Neuron* **33**, 383–395.
- Thakker-Varia, S., *et al.* (2001) "Rab3A is required for brain-derived neurotrophic factor-induced synaptic plasticity: transcriptional analysis at the population and single-cell levels", *J. Neurosci.* **21**, 6782–6790.
- Thompson, S.W., *et al.* (1999) "Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord", *Proc. Natl Acad Sci. USA* **96**, 7714–7718.
- Timmusk, T., *et al.* (1993) "Multiple promoters direct tissue-specific expression of the rat BDNF gene", *Neuron* **10**, 475–489.
- Tolwani, R.J., *et al.* (2002) "BDNF overexpression increases dendrite complexity in hippocampal dentate gyrus", *Neuroscience* **114**, 795–805.
- Tsai, S.J. (2004) "Is mania caused by overactivity of central brain-derived neurotrophic factor?", *Med. Hypotheses* **62**, 19–22.
- Tyler, W.J., Perrett, S.P. and Pozzo-Miller, L.D. (2002) "The role of neurotrophins in neurotransmitter release", *Neuroscientist* **8**, 524–531.
- Wardle, R.A. and Poo, M.M. (2003) "Brain-derived neurotrophic factor modulation of GABAergic synapses by post-synaptic regulation of chloride transport", *J. Neurosci.* **23**, 8722–8732.
- Xu, B., *et al.* (2000) "The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB", *J. Neurosci.* **20**, 6888–6897.
- Xu, B., *et al.* (2003) "Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor", *Nat. Neurosci.* **6**, 736–742.
- Yacoubian, T.A. and Lo, D.C. (2000) "Truncated and full-length TrkB receptors regulate distinct modes of dendritic growth", *Nat. Neurosci.* **3**, 342–349.
- Yamada, K. and Nabeshima, T. (2003) "Brain-derived neurotrophic factor/TrkB signaling in memory processes", *J. Pharmacol. Sci.* **91**, 267–270.
- Yan, Q., *et al.* (1997a) "Immunocytochemical localization of trkB in the central nervous system of the rat", *J. Comp. Neurol.* **378**, 135–157.
- Yan, Q., *et al.* (1997b) "Expression of brain-derived neurotrophic factor protein in the adult rat central nervous system", *Neuroscience* **78**, 431–448.
- Zaccaro, M.C., *et al.* (2001) "p75 Co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains", *J. Biol. Chem.* **276**, 31023–31029.
- Zigova, T., *et al.* (1998) "Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb", *Mol. Cell Neurosci.* **11**, 234–245.
- Zuccato, C., *et al.* (2001) "Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease", *Science* **293**, 493–498.
- Zuccato, C., *et al.* (2003) "Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes", *Nat. Genet.* **35**, 76–83.